HLA spectrum mismatch, variant spectrum differences, distinct etiology: Ningshi Bio uses AHV-201 to fill the unmet gap for Chinese populations that have been ignored by global clinical pipelines.
Suzhou Ningshi Biotech Co., Ltd. (hereinafter referred to as "Ningshi Biotech"), a company seeking RMB 30 million in seed round financing, is advancing a population-based therapeutic oncology vaccine codenamed AHV-201: targeting common solid tumors in China, adopting a fixed multi-epitope antigen combination, and combined with PD-1/PD-L1 for HLA-matched and antigen-positive patients. Its core judgment is that the antigen design of international vaccine pipelines is built on cohorts of European and American populations, which systematically mismatches the Chinese population at three levels: HLA spectrum, somatic mutation profile and tumor etiology, and no one has yet made a systematic layout for this gap.
1. Pain Points and Market: "Population Mismatch" Ignored by International Pipelines
PD-1/PD-L1 inhibitors have reshaped the first-line landscape of oncology treatment, but a considerable proportion of patients still do not respond. Ningshi Biotech puts forward a judgment in its business plan: for most non-responsive patients, the checkpoint pathway has been effectively blocked, and the real gap lies in the upstream — the body lacks sufficient quantity and specific antigen-reactive T cells, which is exactly the link that therapeutic oncology vaccines need to supplement.
The antigen design of vaccines must match the HLA (Human Leukocyte Antigen) of the target population, because peptide-MHC binding is allele-specific. According to its business plan, the antigens of mainstream international pipelines are built on European and American population cohorts: the high-frequency HLA-A*02:01 in European population accounts for about 27.1%, while the highest-frequency allele HLA-A*11:01 in Chinese Han population accounts for about 22.9%, and the frequency of A*02:01 in Chinese Han population is only about 12%. Antigens designed for European and American populations may not stably bind to the MHC groove in Chinese patients, making it difficult for T cells to be effectively activated. In addition, the Chinese population also has systematic differences from European and American populations in somatic mutation profile and tumor etiology, which has formed a consensus in the industry.
The market space on the demand side is also considerable. According to the estimate of the National Cancer Center, there were about 4.8247 million new cases of malignant tumors and about 2.5742 million deaths in China in 2022, ranking first in the world. The five cancer types covered by Ningshi Biotech in the first phase, including lung cancer, colorectal cancer, liver cancer, gastric cancer and esophageal cancer, account for about 67.5% of all cancer deaths (calculated based on the 2022 death data of the National Cancer Center).
Structural differences are more noteworthy than the total amount: liver cancer in China is mainly related to hepatitis B, and the incidence of gastric cancer and esophageal squamous cell carcinoma is significantly higher than that in Europe and the United States. These cancer types have not been prioritized in international vaccine pipelines for a long time. For a vaccine with "adaptation to the Chinese population" as the core, this is not only an unmet clinical need, but also a differentiated market space.
2. Solution and Capability: The "Intermediate Solution" of AHV-201
AHV-201 is a population-based therapeutic oncology vaccine targeting common solid tumors in China. Different from personalized vaccines customized case by case, it adopts a fixed multi-epitope antigen combination, which can be prepared in batches and released in a standardized way; its main clinical positioning is to be used in combination with PD-1/PD-L1, and the target population is screened through HLA typing, antigen expression, immune microenvironment status and previous treatment history. The product has a clear boundary: it is neither an algorithm platform or testing service sold externally, nor a personalized vaccine redesigned and produced for each patient; its indications are not limited to post-operative adjuvant treatment, and it targets patients with advanced, recurrent or progressive disease after standard treatment in the first phase.
In candidate screening, the team has established an auditable funnel: 150 candidate antigens are first compressed to 40 through computational optimization (multimodal evidence integration and presentation prediction), then compressed to 15 through in vitro primary screening (PBMC immunogenicity ELISpot), and then normal tissue expression is excluded through safety filtering of paired paracancerous tissues, and finally 1 group of main candidate combination is frozen with a reserve pool retained. In terms of engineering, low-purity small-batch synthesis is adopted for rough screening, and only the final 15 candidates are scaled up with high purity, so the cost of peptide synthesis is controlled at RMB 390,000.
This solution is at the "intermediate solution" position of the industry's technical route. The mainstream routes of therapeutic oncology vaccines have a trade-off between "matching accuracy of antigens and target population" and "scalability": personalized neoantigen vaccines (such as mRNA-4157, autogene cevumeran) are highly matched with the patient's mutation profile, and adjuvant treatment data has been verified — in August 2026, Moderna and Merck announced that the Phase III trial of mRNA-4157 combined with pembrolizumab has reached the primary endpoints of recurrence-free survival and distant metastasis-free survival in patients with completely resected stage IIB-IV melanoma (according to public information), but the cycle and cost of case-by-case preparation cannot cover the scale of Chinese patients; off-the-shelf shared antigen vaccines (such as IO102-IO103, Tedopi) are scalable with controllable costs, but the antigen selection is relatively rough and lacks population stratification, and the HLA-A2 restricted design of Tedopi is a public case of limited population coverage. AHV-201 sacrifices the matching degree at the individual level in exchange for population-level adaptation and the scalability of the fixed combination.
The track itself is heating up. According to public information, VGX-3100, a therapeutic HPV vaccine from Orient Gene Biotech, reached an exclusive cooperation of RMB 800 million in total with Fosun Pharma in January 2026; XH001, a personalized neoantigen vaccine from NeoCura Bio, was approved for clinical use in 2025 and launched the Phase I trial in October; EVM16 from Everest Medicines announced the first-in-human Phase Ia data at 2026 AACR. For Ningshi Biotech, which is still in the seed round, this means both verified market expectations and the need to manage expectations more prudently.
At present, the project is in the pre-clinical R&D stage. The company says that the antigen discovery and multimodal integrated analysis pipeline has completed methodological verification on the UK cohort, and the construction of the candidate antigen pool and the design of the in vitro verification scheme have been completed; this round of financing corresponds to 18-24 months of key pre-submission verification.
3. Model and Progress: Exchanging Data for Achievements and Assets for Licensing
In terms of business model, Ningshi Biotech cooperates with tertiary hospitals in the mode of "zero fee, no data leaving the country, and achievement return": it returns the full set of multimodal integrated analysis results for free, publishes papers with joint signatures, and jointly applies for funds, in exchange for the existing paired sequencing data of tumor and paracancerous tissues, the real HLA spectrum of Chinese population, clinical annotations and follow-up outcomes, so as to form auditable and due-diligentable data assets. The company emphasizes that the cooperation charges no fees, does not require new sampling, does not change the clinical process, stores and analyzes data domestically, and destroys data as agreed after the cooperation expires. The downstream realizes value through pharmaceutical assets rather than service income: before submission, it advances through equity financing and strategic cooperation on the basis of candidate combinations, immunological data, animal efficacy and patents; after Phase I, it can negotiate regional licensing, joint development and milestone payments with the data of human safety and immunogenicity; after Phase II, it seeks global licensing, merger and acquisition or commercialization cooperation with efficacy signals and biomarker population definition as chips. Its business plan clearly states that it will not take algorithm services, testing services or research outsourcing as sources of income.
In terms of team, Ningshi Biotech has six core members in total, who are from the University of Oxford, Imperial College London, National University of Singapore, University College London and Peking University respectively, covering antigen science and clinical translation, antigen preparation and characterization, artificial intelligence modeling, finance and business analysis. Zhang Aihan, the CEO, is a postdoctoral fellow in the Department of Oncology, University of Oxford, and a PhD of UCL; Shen Jiashu, the CSO, got his bachelor's degree from Peking University and his doctorate and postdoctoral degree from the University of Oxford, once served as co-founder of a start-up company and consultant for pharmaceutical enterprises, with practical experience in drug development, clinical trials and BD. The team also truthfully discloses the gap: there are no full-time personnel in the pharmaceutical (CMC) and registration modules for the time being, and it is planned to solve the problem through senior consultants and the recruitment budget of this round.
This round of RMB 30 million seed round financing corresponds to an 18-24 month pre-submission verification path, covering six stages in turn: candidate discovery and data assets, in vitro primary screening of immunogenicity, candidate combination freezing and animal efficacy, CMC lab test and quality research, safety and stability, pre-submission documents and Phase I protocol, and decision points for continuation or termination are set at the 6th, 12th and 18th months. The failure exit criteria are also set in advance: if the immunogenicity is insufficient for a long time, it will roll back to the alternative combination or restart the screening; if the safety screening fails, the high-risk antigen will be directly removed; if the multi-component preparation cannot be stably prepared, the complexity of the combination will be reduced; if the positive rate of the target population is too low, the indications will be narrowed.
In terms of financing terms, the company plans to transfer 15%-20% of the equity, with a pre-money valuation of RMB 120 million - 170 million (to be negotiated), set up a 15% option pool before investment, with a capital duration of 18-24 months and a 6-month buffer reserved. In terms of capital use, about RMB 10 million for immunological experiments and samples, about RMB 8 million for CMC and quality research, RMB 5 million for team and operation, RMB 3.5 million for data and computing, RMB 3.5 million for safety and registration, and RMB 2 million for intellectual property and legal affairs, totaling RMB 30 million.
It needs to be emphasized that the project is in the pre-clinical stage, and there is no proprietary human immunogenicity data and animal efficacy data yet; the cooperation with many tertiary hospitals is still in the stage of scheme communication, and no formal agreement has been signed; the first batch of patents are being written. The company truthfully lists the above matters as "in progress / not yet completed", and allocates funds by milestone stages, with each item closed correspondingly. This management method of putting uncertainties in advance may be the most noteworthy execution discipline of seed round projects.
The global oncology vaccine track is accelerating. What kind of vaccines do Chinese patients need? Ningshi Biotech's answer is — design antigens for the population first, and then make scalable products. Whether this path can be achieved depends on whether the in vitro immunogenicity data, animal efficacy and CMC research can be delivered by milestones in the next 18-24 months. And an honest pre-clinical project has at least not overdrawn its commitments.